Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment

Kevin Robertson; Alan Landay; Sachiko Miyahara; Alyssa Vecchio; Mary Clare Masters; Todd T. Brown; Babafemi O. Taiwo

doi:10.1007/s13365-019-00795-2

Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment

Kevin Robertson, Alan Landay, Sachiko Miyahara, Alyssa Vecchio, Mary Clare Masters, Todd T. Brown, Babafemi O. Taiwo^*

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The AIDS Clinical Trials Group (ACTG) study A5303 investigated the associations between neuropsychological performance (NP) and inflammatory biomarkers in HIV-infected participants. Fifteen NP tests were administered at baseline and week 48 to 233 ART naïve participants randomized to maraviroc- or tenofovir-containing ART. Neurocognition correlated modestly with markers of lymphocyte activation and inflammation pre-ART (percent CD38+/HLA-DR+(CD4+) (r = − 0.22, p = 0.02) and percent CD38+/HLA-DR+(CD8+) (r = − 0.25, p = 0.02)), and with some monocyte subsets during ART (r = 0.25, p = 0.02). Higher interleukin-6 and percent CD38+/HLA-DR+(CD8+) were independently associated with worse severity of HIV-associated neurocognitive disorders (HAND) (p = 0.04 and 0.01, respectively). More studies to identify HAND biomarkers are needed.

Original language	English (US)
Pages (from-to)	107-113
Number of pages	7
Journal	Journal of neurovirology
Volume	26
Issue number	1
DOIs	https://doi.org/10.1007/s13365-019-00795-2
State	Published - Feb 1 2020

Keywords

Antiretroviral therapy
Biomarker
Inflammation
Monocytes
Neurocognitive performance

ASJC Scopus subject areas

Neurology
Clinical Neurology
Cellular and Molecular Neuroscience
Virology

Access to Document

10.1007/s13365-019-00795-2

Fingerprint Dive into the research topics of 'Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment'. Together they form a unique fingerprint.

Cite this

@article{8dc5f770224340b194b6e89ce02f3f32,

title = "Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment",

abstract = "The AIDS Clinical Trials Group (ACTG) study A5303 investigated the associations between neuropsychological performance (NP) and inflammatory biomarkers in HIV-infected participants. Fifteen NP tests were administered at baseline and week 48 to 233 ART na{\"i}ve participants randomized to maraviroc- or tenofovir-containing ART. Neurocognition correlated modestly with markers of lymphocyte activation and inflammation pre-ART (percent CD38+/HLA-DR+(CD4+) (r = − 0.22, p = 0.02) and percent CD38+/HLA-DR+(CD8+) (r = − 0.25, p = 0.02)), and with some monocyte subsets during ART (r = 0.25, p = 0.02). Higher interleukin-6 and percent CD38+/HLA-DR+(CD8+) were independently associated with worse severity of HIV-associated neurocognitive disorders (HAND) (p = 0.04 and 0.01, respectively). More studies to identify HAND biomarkers are needed.",

keywords = "Antiretroviral therapy, Biomarker, Inflammation, Monocytes, Neurocognitive performance",

author = "Kevin Robertson and Alan Landay and Sachiko Miyahara and Alyssa Vecchio and Masters, {Mary Clare} and Brown, {Todd T.} and Taiwo, {Babafemi O.}",

note = "Funding Information: This research was supported by Award Number U01AI068636 from the National Institute of Allergy and Infectious Diseases and supported by National Institute of Mental Health (NIMH), National Institute of Dental and Craniofacial Research (NIDCR). This work was also supported by other grants from the National Institute of Health AI068634 and AI068636 to ACTG Statistical Data Analysis Center and to the research sites that participated in the study. Funding Information: T.T. B. as served as a consultant for Bristol-Myers Squibb, GlaxoSmithKline, Merck, AbbVie, Gilead, ViiV, Theratechnologies, and EMD-Serono and has received research funding from Merck and GlaxoSmithKline. ",

year = "2020",

month = feb,

day = "1",

doi = "10.1007/s13365-019-00795-2",

language = "English (US)",

volume = "26",

pages = "107--113",

journal = "Journal of NeuroVirology",

issn = "1355-0284",

publisher = "Springer New York",

number = "1",

}

Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment. / Robertson, Kevin; Landay, Alan; Miyahara, Sachiko; Vecchio, Alyssa; Masters, Mary Clare; Brown, Todd T.; Taiwo, Babafemi O.

In: Journal of neurovirology, Vol. 26, No. 1, 01.02.2020, p. 107-113.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment

AU - Robertson, Kevin

AU - Landay, Alan

AU - Miyahara, Sachiko

AU - Vecchio, Alyssa

AU - Masters, Mary Clare

AU - Brown, Todd T.

AU - Taiwo, Babafemi O.

N1 - Funding Information: This research was supported by Award Number U01AI068636 from the National Institute of Allergy and Infectious Diseases and supported by National Institute of Mental Health (NIMH), National Institute of Dental and Craniofacial Research (NIDCR). This work was also supported by other grants from the National Institute of Health AI068634 and AI068636 to ACTG Statistical Data Analysis Center and to the research sites that participated in the study. Funding Information: T.T. B. as served as a consultant for Bristol-Myers Squibb, GlaxoSmithKline, Merck, AbbVie, Gilead, ViiV, Theratechnologies, and EMD-Serono and has received research funding from Merck and GlaxoSmithKline.

PY - 2020/2/1

Y1 - 2020/2/1

N2 - The AIDS Clinical Trials Group (ACTG) study A5303 investigated the associations between neuropsychological performance (NP) and inflammatory biomarkers in HIV-infected participants. Fifteen NP tests were administered at baseline and week 48 to 233 ART naïve participants randomized to maraviroc- or tenofovir-containing ART. Neurocognition correlated modestly with markers of lymphocyte activation and inflammation pre-ART (percent CD38+/HLA-DR+(CD4+) (r = − 0.22, p = 0.02) and percent CD38+/HLA-DR+(CD8+) (r = − 0.25, p = 0.02)), and with some monocyte subsets during ART (r = 0.25, p = 0.02). Higher interleukin-6 and percent CD38+/HLA-DR+(CD8+) were independently associated with worse severity of HIV-associated neurocognitive disorders (HAND) (p = 0.04 and 0.01, respectively). More studies to identify HAND biomarkers are needed.

AB - The AIDS Clinical Trials Group (ACTG) study A5303 investigated the associations between neuropsychological performance (NP) and inflammatory biomarkers in HIV-infected participants. Fifteen NP tests were administered at baseline and week 48 to 233 ART naïve participants randomized to maraviroc- or tenofovir-containing ART. Neurocognition correlated modestly with markers of lymphocyte activation and inflammation pre-ART (percent CD38+/HLA-DR+(CD4+) (r = − 0.22, p = 0.02) and percent CD38+/HLA-DR+(CD8+) (r = − 0.25, p = 0.02)), and with some monocyte subsets during ART (r = 0.25, p = 0.02). Higher interleukin-6 and percent CD38+/HLA-DR+(CD8+) were independently associated with worse severity of HIV-associated neurocognitive disorders (HAND) (p = 0.04 and 0.01, respectively). More studies to identify HAND biomarkers are needed.

KW - Antiretroviral therapy

KW - Biomarker

KW - Inflammation

KW - Monocytes

KW - Neurocognitive performance

UR - http://www.scopus.com/inward/record.url?scp=85072052448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072052448&partnerID=8YFLogxK

U2 - 10.1007/s13365-019-00795-2

DO - 10.1007/s13365-019-00795-2

M3 - Article

C2 - 31468473

AN - SCOPUS:85072052448

VL - 26

SP - 107

EP - 113

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 1

ER -